Dataset Information

The integration of network pharmacology and multiomics reveals the mechanism by which Malus hupehensis leaves inhibit acute liver injury

ABSTRACT:

Objective: The leaves of Malus hupehensis (MH) are a medicinal and edible traditional Chinese medicine (TCM) with good liver protection, although its underlying mechanism remains unclear. In this study, a network pharmacology-integrated multi-omics method was used to explore the hepatoprotective mechanism of MH.

Methods: The in vivo and in vitro components of MH were identified using ultra-performance liquid chromatography coupled with Q Exactive Orbitrap mass spectrometry (UPLC Q Exactive Orbitrap MS). The targets and related pathways through which MH inhibits acute liver injury (ALI) were predicted by network pharmacology. The liver protective potential of MH was evaluated in a carbon tetrachloride-induced ALI model in C57BL/6J mice. The mechanism of MH was explored by integrating network pharmacology and multi-omics and verified by immunohistochemistry, Western blot, and RT-qPCR analyses.

Results: Our analysis revealed 121 in vitro and 20 in vivo components of MH. Network pharmacology analysis showed that the prototype components of MH, phlorizin and phloretin, were involved in inflammation and metabolism-related pathways. In vivo experiments revealed that MH significantly inhibited carbon tetrachloride-induced ALI in mice through antioxidant and anti-inflammatory effects. Combined network pharmacology and multi-omics analyses revealed that MH protected the liver by inhibiting the activation of the MAPK signaling pathway and regulating metabolic reprogramming, specifically with respect to lipid and amino acid metabolism.

Conclusions: Our study suggests that MH exerts a protective effect against carbon tetrachloride-induced ALI in mice, potentially by inhibiting MAPK signaling and regulating lipid and amino acid metabolic reprogramming. These findings provide a preliminary basis for exploring MH as a potential candidate for the prevention and treatment of ALI.

INSTRUMENT(S): Liquid Chromatography MS - positive - hilic, Liquid Chromatography MS - negative - hilic

PROVIDER: MTBLS13219 | MetaboLights | 2026-05-01

REPOSITORIES: MetaboLights

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	a_MTBLS13219_LC-MS_negative_hilic.txt	Txt
	a_MTBLS13219_LC-MS_positive_hilic.txt	Txt
	i_Investigation.txt	Txt
	m_MTBLS13219_LC-MS_negative_hilic_v2_maf.tsv	Tabular
	m_MTBLS13219_LC-MS_positive_hilic_v2_maf.tsv	Tabular

Items per page:

1 - 5 of 6

Similar Datasets

Project description:Background: Heterotopic ossification (HO), characterized by pathological bone formation in extra-skeletal tissues such as tendon, often results in debilitating tissue dysfunction. HO of tendons primarily arises from abnormal osteogenic differentiation of tendon stem cells following injury. Despite being a common clinical occurrence, the cellular and molecular mechanisms of tendon HO are poorly understood, and effective treatments remain elusive. Farnesol, a natural isoprenoid alcohol abundant in citrus fruits, lavender, and royal jelly, is known for its potent anti-inflammatory, antioxidant, and antitumor properties. However, its applications in tissue engineering are rarely explored, particularly in musculoskeletal repair. Here, we provide the first report on the therapeutic potential of Farnesol in attenuating tendon HO and elucidate the associated molecular mechanisms.Methods: This study evaluated the effects of Farnesol on osteogenic differentiation of tendon-derived stem cells using both in vitro and in vivo models. The molecular mechanisms underlying the therapeutic effects of Farnesol on tendon HO were revealed by RNA sequencing combined with network pharmacology analysis, identifying the GSTP1/MAPK axis as a potential target pathway. In vitro rescue experiments using a specific GSTP1 inhibitor were conducted to confirm whether Farnesol primarily exerted its therapeutic effects through GSTP1.Results: The results demonstrated significant effects of Farnesol on attenuating tendon HO both in vitro and in vivo. Combined analysis of transcriptomics and network pharmacology indicated that Farnesol functions by targeting the GSTP1/MAPK signaling axis. These findings were further validated by in vitro experiments using the GSTP1 inhibitor, which reversed the suppressive effects of Farnesol on osteogenesis.Conclusion: Farnesol inhibits the progression of post-traumatic tendon HO by targeting the GSTP1/MAPK pathway. These findings provide new insights into the potential of using Farnesol as a therapeutic agent for HO.

Project description:Background: Triple-negative breast cancer (TNBC) urgently needs effective therapies due to limited targeted options and unfavorable outcomes. We investigated Trichosanthes kirilowii Maxim formula granules (TKM) using integrated network pharmacology, metabolomics, and molecular pharmacology to clarify potential multi-target mechanisms relevant to TNBC.Methods: Liquid chromatography coupled with mass spectrometry was employed to identify the components of TKM formula granules. Network pharmacology-based prediction was used to uncover potential mechanisms by which TKM counteracts TNBC. Potential targets were identified, and pathway enrichment analysis was performed. Subsequently, TNBC cells and 4T1 tumor-bearing mice were used to verify the molecular mechanisms of TKM.Results: We identified 151 active compounds in TKM. Through network pharmacology analysis, 214 TNBC-related targets were found, with 28 core targets, including cell cycle and apoptosis regulators MYC, TP53, AKT1, CCND1, CASP3, PIK3CA, BCL2L1, and CDC42. The compound-target-pathway-disease network showed that schisandrin binds to many treatment targets with satisfactory docking performance, especially for MYC and AKT1. Experimentally, TKM was found to significantly promote apoptosis and induce G2/M-phase cell-cycle arrest in MDA-MB-231 cells. Western blot analysis showed that TKM suppressed PI3K/AKT and Wnt/β-catenin signaling pathways. Surface plasmon resonance experiment revealed that schisandrin binds to recombinant AKT1 with an equilibrium dissociation constant (K_D) of 0.1525 mM. According to untargeted metabolomics results, TKM can regulate amino acid, glycine, serine, and threonine metabolism, mineral absorption, protein digestion and absorption, central carbon metabolism, and arginine biosynthesis to exert therapeutic effects on TNBC. All findings were consistent with predicted targets and pathways.Conclusion: This study comprehensively explores the multi-target mechanisms of TKM against TNBC using network pharmacology, molecular pharmacology, and metabolomics approaches. These findings provide a foundation for future mechanistic investigations and may support the further preclinical development of TKM-based strategies for TNBC.

Dataset Information

The integration of network pharmacology and multiomics reveals the mechanism by which Malus hupehensis leaves inhibit acute liver injury

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets